双歧杆菌三联活菌胶囊联合美沙拉嗪治疗溃疡性结肠炎的疗效评价

Evaluation of efficacy of live combined bifidobacterium,lactobacillus and enterococcus capsules combined with mesalamine in the treatment of ulcerative colitis

目的探讨双歧杆菌三联活菌胶囊联合美沙拉嗪治疗溃疡性结肠炎的临床疗效。方法78例溃疡性结肠炎患者,随机分为对照组和观察组,各39例。对照组予以美沙拉嗪联合复方谷氨酰胺肠溶胶囊治疗,观察组采用双歧杆菌三联活菌胶囊联合美沙拉嗪治疗。比较两组患者治疗前后溃疡性结肠炎功能指数评分及治疗后不良症状发生情况。结果治疗前,两组患者消化功能、免疫功能、排毒功能、运输功能评分比较,差异无统计学意义(P>0.05);治疗后,两组患者消化功能、免疫功能、排毒功能、运输功能评分均高于治疗前,且观察组患者消化功能评分(37.29±7.18)分、免疫功能评分(20.08±3.27)分、排毒功能评分(36.27±4.95)分、运输功能评分(32.39±4.21)分均高于对照组的(29.26±3.18)、(15.39±2.37)、(19.29±3.31)、(13.21±3.94)分,差异具有统计学意义(P<0.05)。观察组患者不良症状发生率12.82%低于对照组的58.97%,差异具有统计学意义(P<0.05)。结论针对慢性溃疡性结肠炎患者,双歧杆菌三联活菌胶囊联合美沙拉嗪治疗具有较高的应用价值,可有效减少不良症状的发生,利于患者肠胃功能的恢复,改善患者生活质量,值得推广和应用。

Objective To discuss the clinical efficacy of live combined bifidobacterium,lactobacillus and enterococcus capsules combined with mesalamine in the treatment of ulcerative colitis.Methods A total of 78 patients with ulcerative colitis were randomly divided into control group and observation group,with 39 cases in each group.The control group was treated with mesalazine combined with compound glutamin entersoluble capsules,and the observation group was treated with live combined bifidobacterium,lactobacillus and enterococcus capsules combined with mesalazine.The ulcerative colitis functional index score before and after treatment,and the occurrence of adverse symptoms after treatment were compared between the two groups.Results Before treatment,there was no statistically significant difference in the scores of digestive function,immune function,detoxification function and transportation function between the two groups(P>0.05).After treatment,the scores of digestive function,immune function,detoxification function and transportation function of the two groups were higher than those of this group before treatment;the digestive function score(37.29±7.18)points,immune function score(20.08±3.27)points,detoxification function score(36.27±4.95)points and transport function score(32.39±4.21)points in the observation group were higher than(29.26±3.18),(15.39±2.37),(19.29±3.31),and(13.21±3.94)points in the control group;all the differences were statistically significant(P<0.05).The incidence of adverse symptoms 12.82% in the observation group was lower than 58.97% in the control group,and the difference was statistically significant(P<0.05).Conclusion For patients with chronic ulcerative colitis,live combined bifidobacterium,lactobacillus and enterococcus capsules combined with mesalazine has high application value.It can reduce the occurrence of adverse symptoms,improve the quality of life of patients,and is conducive to the recovery of gastrointestinal function,which is worthy of promotion and application.